NephroGenex Licenses Diabetic Nephropathy Drug
Posted on: Thursday, 11 May 2006, 21:04 CDT
US biotech company NephroGenex has acquired rights to the investigational drug Pyridorin for the treatment of diabetic nephropathy and acute renal failure.
The company licensed the rights to commercialize the drug in diabetic neuropathy from North Carolina-based Biostratum, while it acquired the commercial rights to the drug in acute renal failure from Vanderbilt University. Financial details for either of the deals have not been made public.
In diabetic neuropathy, Pyridorin has been evaluated in two phase II clinical trials demonstrating in both a significant treatment effect in stemming the progression of the disorder.
According to the company, developing treatments for diabetic nephropathy is problematic because of significant patient variability in the progression of the disease. As a result, adequate powering of phase III trials necessitates large patient populations and long treatment periods. This has been a major obstacle in the development of therapies for this debilitating and costly disease.
Recent advances in molecular urinalysis have determined biomarkers that can identify with a high level of accuracy diabetic patients with nephropathy. NephroGenex is expanding on these advances to identify diabetic nephropathy 'progressors' for recruitment into phase III clinical trials.
By removing 'non-progressors' from the trial, the prospects for demonstrating a significant treatment effect are dramatically improved.
Source: Datamonitor
Related Articles
- Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
- FDA Approval Sought For Once-Weekly Diabetes Treatment
- Global Media Networks, Inc. Announces Biocure Med Inc. Has Obtained Confirmed Positive Results From Pre-Clinical Diabetes Treatment of Proprietary Product DiaCure(TM)
- Regenetech, Johns Hopkins University Collaborate for Diabetes Treatment
- Natural Antioxidants Help Reduce Oxidative Stress in Diabetes Treatment
- WunderMarx Launches Web Site for UC Irvine Center for Diabetes Treatment and Research
- View Results of the Latest ChangeWave Research Trends in Generic Drugs and Diabetes Treatments (July 2006)
- Takeda Pharmaceutical Acquires Rights to Diabetes Treatment Agent
- The Obesity Epidemic As Harbinger of a Metabolic Disorder Epidemic: Trends in Overweight, Hypercholesterolemia, and Diabetes Treatment in Geneva, Switzerland, 1993-2003
- Diabetic Treatment Centers of America Announces Letter of Intent to Acquire Movement Disorder Technologies
 |
 |
User Comments (0)
RSS Feeds